Short versus long course therapy in the treatment of febrile urinary tract infections in men based on serum PSA values

Published:October 21, 2022DOI:


      • Shortening antimicrobial treatments is essential to avoid the emergence of antibiotic resistance.
      • Duration of therapy for febrile urinary tract infections in men had not been well stablished.
      • Serum PSA could guide the duration of therapy based on prostatic involvement.
      • A short duration therapy (14 days) is a safe option in patients with normal serum PSA values.



      Febrile urinary tract infections (fUTI) in men are frequently complicated with subclinical prostatic involvement, measured by a transient increase in serum prostate-specific-antigen (sPSA). The aim of this study was to evaluate recurrence rates in a 6-month follow-up period of 2-week versus 4-week antibiotic treatment in men with fUTI, based on prostatic involvement. Clinical and microbiological cure rates at the end-of-therapy (EoT) were also assessed.


      Open label, not-controlled, prospective study. Consecutive men diagnosed of fUTI were included. Duration of therapy was 2 weeks for patients with a sPSA level <5mg/L (short duration therapy, SDT) or 4 weeks for PSA >5 mg/L (long duration therapy, LDT).


      Ninety-one patients were included; 19 (20%) received SDT. Median age was 56.9 years (range 23-88). Bacteremia was present in 9.8% of patients (Escherichia coli was isolated in 91%). Both groups had similar demographic, clinical characteristics and laboratory findings. Median PSA levels were 2.3 mg/L in the SDT group vs 23.4 mg/L in the LDT group. In the 6-month visit, 26% of patients had achieved complete follow-up. Nonsignificant differences between groups were found neither in recurrence rates after 6 months (9% in SDT vs 10% in LDT) nor in clinical or microbiological cure rates at EoT (100% in SDT vs 95% in LDT and 95% in SDT vs 93% in LDT respectively).


      One fifth of men with fUTI did not present apparent prostatic involvement. A 2-week regimen seems adequate in terms of clinical, microbiological cure and recurrence rates for those patients without PSA elevation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Winberg J
        • Andersen HJ
        • Bergström T
        • Jacobsson B
        • Larson H
        • Lincoln K.
        Epidemiology of symptomatic urinary tract infection in childhood.
        Acta Paediatr Scand Suppl. 1974; : 1-20
        • Ulleryd P.
        Febrile urinary tract infection in men.
        Int J Antimicrob Agents. 2003; 22: 89-93
        • Collins MM
        • Stafford RS
        • O'Leary MP
        • Barry MJ.
        How common is prostatitis? A national survey of physician visits.
        J Urol. 1998; 159: 1224-1228
        • Czaja CA
        • Scholes D
        • Hooton TM
        • Stamm WE.
        Population-based epidemiologic analysis of acute pyelonephritis.
        Clin Infect Dis. 2007; 45: 273-280
        • Ulleryd P
        • Zackrisson B
        • Aus G
        • Bergdahl S
        • Hugosson J
        • Sandberg T.
        Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography.
        BJU Int. 1999; 84: 470-474
        • Lipsky BA
        • Byren I
        • Hoey CT.
        Treatment of bacterial prostatitis.
        Clin Infect Dis. 2010; 50: 1641-1652
        • Morel CM
        • Mossialos E.
        Stoking the antibiotic pipeline.
        Bmj. 2010; 340: c2115
        • Modi SR
        • Collins JJ
        • Relman DA.
        Antibiotics and the gut microbiota.
        J Clin Invest. 2014; 124: 4212-4218
        • Spellberg B.
        The New Antibiotic Mantra-"Shorter Is Better".
        JAMA Intern Med. 2016; 176: 1254-1255
        • Ulleryd P
        • Sandberg T.
        Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up.
        Scand J Infect Dis. 2003; 35: 34-39
        • Gleckman R
        • Crowley M
        • Natsios GA.
        Therapy of recurrent invasive urinary-tract infections of men.
        N Engl J Med. 1979; 301: 878-880
        • Smith JW
        • Jones SR
        • Reed WP
        • Tice AD
        • Deupree RH
        • Kaijser B.
        Recurrent urinary tract infections in men. Characteristics and response to therapy.
        Ann Intern Med. 1979; 91: 544-548
        • Sabbaj J
        • Hoagland VL
        • Cook T.
        Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men.
        Scand J Infect Dis Suppl. 1986; 48: 48-53
        • van Nieuwkoop C
        • van der Starre WE
        • Stalenhoef JE
        • van Aartrijk AM
        • van der Reijden TJ
        • Vollaard AM
        • et al.
        Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.
        BMC Med. 2017; 15: 70
        • Ulleryd P
        • Zackrisson B
        • Aus G
        • Bergdahl S
        • Hugosson J
        • Sandberg T.
        Selective urological evaluation in men with febrile urinary tract infection.
        BJU Int. 2001; 88: 15-20
        • Ronald AR.
        Current concepts in the management of urinary tract infections in adults.
        Med Clin North Am. 1984; 68: 335-349
        • Schaeffer AJ.
        Urinary tract infection in men–state of the art.
        Infection. 1994; 22: S19-S21
        • Nicolle LE.
        A practical guide to antimicrobial management of complicated urinary tract infection.
        Drugs Aging. 2001; 18: 243-254
        • Drekonja DM
        • Rector TS
        • Cutting A
        • Johnson JR.
        Urinary tract infection in male veterans: treatment patterns and outcomes.
        JAMA Intern Med. 2013; 173: 62-68
        • Arjunlal TS
        • Deepanjali S
        • Manikandan R
        • Medha R.
        Frequency and clinical significance of prostatic involvement in men with febrile urinary tract infection: a prospective observational study.
        F1000Res. 2020; 9: 617